Drug Approval | June 23, 2026
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
